4.6 Article

A heterobifunctional molecule recruits cereblon to an RNA scaffold and activates its PROTAC function

Journal

CELL REPORTS PHYSICAL SCIENCE
Volume 3, Issue 10, Pages -

Publisher

CELL PRESS
DOI: 10.1016/j.xcrp.2022.101064

Keywords

-

Funding

  1. National Natural Science Foundation of China [22177111, 21907090, 21877108]
  2. Sichuan Science and Technology Program [2019ZDZX0048, 2020YFS0370]
  3. Sichuan Medical Research Program [S20005]
  4. Chengdu Municipal Bureau of Science and Technology [2021-YF05-01739-SN]
  5. Youth Innovation Promotion Association CAS [2020365]

Ask authors/readers for more resources

The ability to regulate protein abundance provides opportunities for disease treatments. PROTAC, as a promising technology, utilizes RNA aptamers to target and degrade multiple target proteins. Aptamer-based PROTAC technology offers a general strategy for targeted protein degradation in drug discovery and biological research.
The ability to regulate protein abundance provides huge opportunities for the development of treatments for various diseases. The proteolysis-targeting chimera (PROTAC) provides powerful tools to degrade these undruggable targets, becoming a promising technology. Herein, we report the development of aptamer-based PROTACs as a novel strategy to broaden the spectrum of targets. The RNA aptamer of the target protein applied in targeted degradation. A heterobifunctional molecule can recruit E3 ubiquitin ligase to a genetically encoded tandem aptamer RNA scaffold, promoting ubiquitination and degradation of target proteins. Partial degradations of different target proteins, including p50, p65, and E2F1, have been achieved by simply replacing the 3' module on the RNA scaffold with the corresponding RNA aptamers. Besides, simultaneous degradation of multiple target proteins is realized through inserting more aptamer into RNA scaffold. Thus, the aptamer-based PROTAC technology offers a general strategy for targeted protein degradation in drug discovery and biological research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available